renibus therapeutics

PREVENT. PROTECT. IMPROVE.

We are Dedicated to Transforming the Cardio, Renal and Metabolic Diseases Treatment Paradigm



About Us

Renibus is a clinical stage biopharmaceutical company dedicated to treating, improving, and extending patients' lives by developing products to prevent disease progression, improve outcomes and protect against organ damage associated with cardio, renal and metabolic diseases. Renibus' first-in-a-new class lead program is RBT-1 (stannic protoporfin / iron sucrose), a single dose IV drug that is given over 1-2 hours, 24-48 hours prior to patients undergoing elective cardiac and/or valve surgery. It is in a Phase 3 pivotal trial (called PROTECT) to reduce the risk of post operative complications and improve outcomes following cardiothoracic surgery. The drug has received FDA Breakthrough and Fast Track Designations.

Veverimer is an oral, non-absorbed hydrochloric acid binder that was acquired from Tricida. The drug has received FDA Orphan Drug Designation. We are currently evaluating veverimer in preclinical models and analyzing historical data to further our understanding of its clinical profile with a goal of identifying an indication for evaluation in clinical trials. Renibus has three additional assets at earlier stages of development.

Quick Facts:

Founded in 2016
Headquartered in Southlake, TX

Lead program, RBT-1, in Ph 3 PROTECT Study to reduce the risk of post-operative complications after cardiac surgery



Leadership Team

D. Jeff Keyser, RPh, JD, PhD, *President & Chief Executive Officer*
Bhupinder Singh, MD, *Chief Medical Officer*
Jamie A. Donadio, *Chief Financial Officer*
Asha Ramdas, *Chief Technical Officer*

Board of Directors

Henrik Rasmussen, MD, PhD, *Chairman*
D. Jeff Keyser, RPh, JD, PhD, *President & Chief Executive Officer*
Bhupinder Singh, MD, *Director*
Carlos Guillem, MBA, PhD, *Director*

Developing breakthrough products.

We have developed a robust portfolio of products that act by activating multiple cytoprotective pathways.

Program	Indication/Condition	Pre-clinical	Phase 1	Phase 2	Phase 3	Rights
RBT-1 Stannic protoporfin/iron sucrose	Reducing the risk of post op complications in cardiothoracic surgery					renibus therapeutics
Veverimer	Undisclosed					renibus therapeutics
Additional Programs						renibus therapeutics

Our patients are the core of what we do.

- Topline results expected in Q3 2025
- Enrollment is complete (n=400) in PROTECT, a pivotal Phase 3 trial evaluating the effect of RBT-1 on reducing the risk of post-operative complications in patients undergoing cardiac surgery (NCT06021457).
- The trial enrolled 423 patients across 40 trial sites in the United States (US) and Canada.

protect

RBT-1 Pivotal Phase 3 Study

Enrollment Complete

Learn more at renibus.com/patients

"On behalf of Renibus and the clinical study team, I would like to thank the patients and study investigators who supported this important study."

Bhupinder Singh, M.D., F.A.S.N., F.N.K.F.
Chief Medical Officer, Renibus Therapeutics

renibus therapeutics

To learn more about Renibus visit renibus.com or scan the QR code to the right.

View our Publications